Video Experimental Relacionado
Updated: May 16, 2026
10:23
Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model
Published on: November 13, 2012
Los análisis genómicos integradores identifican el MITF como un oncogén de supervivencia de linaje amplificado en el
Levi A Garraway1, Hans R Widlund, Mark A Rubin
1Department of Medical Oncology, and Melanoma Program in Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA.
Nature
|July 8, 2005
Resumen
La amplificación del factor de transcripción asociado a la microftalmia (MITF) impulsa la progresión del melanoma y reduce la supervivencia del paciente. Dirigirse al MITF ofrece una estrategia terapéutica potencial para este cáncer resistente a la quimioterapia.
Área de la Ciencia:
- La genómica es la genómica.
- Biología del cáncer Biología del cáncer.
- Oncología Molecular Oncología Molecular
Sus antecedentes:
- Los análisis del genoma del cáncer revelan alteraciones genéticas que impulsan el desarrollo de tumores.
- Las matrices de polimorfismo de un solo nucleótido (SNP) identifican alteraciones en el número de copias y eventos de pérdida de heterocigosidad.
Objetivo del estudio:
- Identificar nuevas alteraciones genéticas en el melanoma.
- Investigar el papel del MITF en la génesis y progresión del melanoma.
- Explorar estrategias terapéuticas dirigidas al MITF.
Principales métodos:
- Datos de matriz SNP integrados con firmas de expresión génica de líneas celulares NCI60.
- Analizó la prevalencia de amplificación MITF y su correlación con los resultados clínicos.
- Utilizó la expresión ectópica de MITF y el mutante BRAF (V600E) en melanocitos humanos primarios.
- Evaluó el efecto de la reducción de MITF en la quimiosensibilidad.
Principales resultados:
- Identificó la amplificación MITF como un nuevo oncogén del melanoma.
- La amplificación de MITF fue más frecuente en el melanoma metastásico y se relacionó con una menor supervivencia.
- La amplificación de MITF ocurrió junto con la mutación de BRAF y la inactivación de p16.
- Expresión de MITF ectópico con BRAF ((V600E) melanocitos transformados.
- La actividad reducida del MITF sensibilizó las células de melanoma a la quimioterapia.
Conclusiones:
- El MITF funciona como un oncogén del melanoma y un factor de "supervivencia del linaje".
- La amplificación del MITF es un factor clave en la progresión y metástasis del melanoma.
- Dirigirse al MITF, potencialmente con inhibidores de BRAF o CDK, presenta un enfoque terapéutico prometedor para el melanoma.
Videos de Conceptos Relacionados
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...